Protinah to Attend BIO USA 2026, Discussing Technology Collaboration

Protinah will participate in the 'BIO International Convention 2026' (BIO USA) to be held from June 22 to 25.

On June 17, Protinah announced that it plans to hold partnering meetings with several global pharmaceutical companies, focusing on its osteoarthritis treatment candidate 'PRT-101' and obesity/diabetes treatment candidate 'PRT-1309', both discovered through its proprietary antibody design platform.

The osteoarthritis treatment candidate PRT-101 recently demonstrated its effects on cartilage regeneration and pain relief by releasing non-clinical direct comparison data with Lorecivivint, a phase 3 clinical candidate, at the European Congress of Rheumatology (EULAR 2026). The company intends to continue discussions with international pharmaceutical companies—where there is high demand for disease-modifying osteoarthritis drugs (DMOADs)—regarding subsequent clinical development and commercialization strategies.

The obesity and diabetes treatment candidate PRT-1309 presented pharmacokinetic (PK) data at the American Diabetes Association (ADA 2026) showing that a single administration in mice maintained weight loss effects for four weeks. Additional weight loss benefits were also observed when combined with glucagon-like peptide-1 (GLP-1) drugs.

Protinah will also discuss technology collaborations based on its proprietary antibody design platform, 'PPI Landscape.' At this year's BIO USA, the company plans to showcase its capabilities in generating big data on antibody-antigen interactions, AI-driven design technology, and the 'Lab-in-the-loop' system, which verifies these technologies through large-scale experiments.

A Protinah representative stated, "BIO USA is an important opportunity to directly present our proprietary antibody design platform and key pipeline candidates discovered through it to global pharmaceutical companies, and to concretely discuss commercialization prospects. Beyond business development centered on individual pipeline candidates, we aim to expand the scope of collaboration through platform-based joint research and technology alliances."

This content was produced with the assistance of AI translation services.